Podcasts about wexner medical center

The City of Ohio State podcast welcomes back Kristin Poldemann, associate vice president of Facilities Design and Construction, joined by Garth Dahdah, senior director of Capital Projects and Space Planning for Ambulatory Services and the Wexner Medical Center. From major projects like Outpatient Care Powell to smaller but essential initiatives, they share insights on innovation, efficiency and teamwork.Read video transcript: https://ap.osu.edu/sites/default/files/documents/Transcript%20for%20the%20City%20of%20Ohio%20State%20Podcast%20Season%204%20Episode%203.docx

MedFlight Radio starts out 2025 with a bang as we do our first polytrauma case review with a scene trauma run to one of our ownership's hospital Level one trauma Facility--The Ohio State Medical Center.    We did this in a two-part series to highlight the prehospital side of things with MedFlight on the scene and then part two focuses on the hospital side of things and the care throughout the hospital course.    This podcast covers this trauma case study from the original call to MedFlight to the patient hospital discharge.  Come listen in.  

TopMedTalk brings you exclusive, cutting-edge conversations from Anesthesiology 2024, the American Society of Anesthesiologists (ASA) annual general meeting; as is traditional, we always speak with the outgoing and incoming Presidents of the ASA. This podcast is taken from the final day of our coverage. Make sure you are subscribed to TopMedTalk so you can hear all of our coverage -as we release it- over the next few months. Presented by Desiree Chappell and Mike Grocott with their guests, Donald Arnold, MD, FACHE, FASA, Incoming ASA President president of Western Anesthesiology Associates, Inc., chair of anesthesiology at Mercy Hospital St. Louis and Ronald Harter, MD, FASA, Outgoing ASA President, Jay J. Jacoby professor and chair of the Department of Anesthesiology at The Ohio State University College of Medicine in Columbus, and physician anesthesiologist at the University's Wexner Medical Center.

Ohio State stands at the doorway of great opportunity, firmly and uniquely positioned to be a leading national flagship public research university. Leading the way is Walter "Ted" Carter Jr., who was appointed as the 17th president of The Ohio State University by the Board of Trustees on August 22, 2023. He began his tenure at Ohio State on January 1, 2024.rnrnAs president, Carter leads the state's flagship, public research university with six campuses in Ohio and a student body of more than 65,000. Ohio State's largest campus is in Columbus, the state capital and one of the fastest growing cities in the country. Additionally, the university has campuses in Lima, Mansfield, Marion, Newark and Wooster, as well as the nationally recognized Wexner Medical Center, a global research enterprise and leading athletics program.

Dr. Barbara Bawer, Ohio State University Wexner Medical Center—Checklist for Back-to-College Wellness.Barbara Bawer MD | Ohio State University Wexner Medical Center (osu.edu)The Ohio State University Wexner Medical Center (osu.edu)  Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Barbara Bawer, Ohio State University Wexner Medical Center—Checklist for Back-to-College Wellness. Barbara Bawer MD | Ohio State University Wexner Medical Center (osu.edu) The Ohio State University Wexner Medical Center (osu.edu)  

The mission of Chyke Doubeni, MD, MPH, is clear. “I believe everyone deserves the right and opportunity to get the best care possible and I believe people who have socioeconomic and other barriers need not be prevented from getting that care,” said the Wexner Medical Center's Chief Health Equity Officer and the OSUCCC- James Associate Director for Diversity, Equity and Inclusion. “All of us at the Wexner and James are very motivated by our mission to insure that everyone in Ohio has the best healthcare possible.” Dr. Doubeni is a family doctor and his research focuses on the effectiveness of screenings, such as colonoscopies, lung cancer and breast cancer screenings and recognizing and overcoming the social determinants of health. “These social factors are major contributors to poor health outcomes for underserved communities and understanding and addressing these barriers is crucial and my role is to create the processes to allow us to do this with better fidelity,” he said. His goal for the James is to provide better educational, screening, testing and treatment options to underserved populations in Columbus and in rural areas of Ohio, such as Appalachia. One of the ways to do this, Doubeni explained, “is to go to people where they are … with our mobile lung cancer van, our mobile breast cancer van and a free colonoscopy program run by the staff of the Wexner and James who volunteer their time.” Colon cancer screenings are another important area. The James is in the midst of what Dr. Doubeni called a pilot program in which people are given a fecal immunochemical test (FIT) that that is not invasive and that they can take at home to detect this all-too common type of cancer. “Our hope is to reach even more people who wouldn't otherwise be screened,” he said. The James is also leading the way in using circulating tumor DNA to detect cancer in its early stages. “We have found ways to use a liquid biopsy, a blood sample, to detect cancer in the blood,” Dr. Doubeni said. This type of screening is still in the early stages, shows great promise and could be effective in reaching underserved populations.

Dr. Spero Cataland, Professor of Internal Medicine and the Benign Hematology Section Head at The Ohio State University, Wexner Medical Center, is currently serving as chair of i3 Health's free CME/NCPD activity and Hematology Fellows Lecture Series, Current Standards and New Directions in Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). In this interview, Dr. Cataland provides an update on new research that has occurred in the field during the past year and shares a preview of what learners can look forward to when attending his presentation at their own institution.

This forum is part of CMC's Optimal Health Series. Columbus may still be working toward an overall identity as a city, but leaders in healthcare have already put the region on the globe as a worldwide hub for health. Central Ohio is now home to four major hospital systems and a growing number of global leaders in therapeutics and medical technology. With the new heads of The Ohio State University's Wexner Medical Center and Cardinal Health, we dive into a conversation on what the future holds for advanced healthcare in Central Ohio and around the world.  Featuring: Jason Hollar, Chief Executive Officer, Cardinal Health John Warner, MD, Chief Executive Officer, The Ohio State University Wexner Medical Center and Executive Vice President, Ohio State  The host is Tracy Townsend, Anchor & Medical Correspondent, WBNS-10TV The presenting sponsors of CMC's Optimal Health Series are The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, and OhioHealth. The sponsors of this forum were The United Way of Central Ohio, Cardinal Health, Ohio Life Sciences, and The Columbus Partnership. This forum was supported by The Ellis. The livestream presenting sponsor was The Center for Human Kindness at The Columbus Foundation. The livestream partner was The Columbus Dispatch. This forum was recorded before a live audience at The Ellis in Columbus, Ohio's historic Italian Village on March 20, 2024. 

“I'm such a planner. I want to know everything ahead of time and plan for things. [I make] lists for work, packing, groceries– I have to have a list for everything.” Credentialing specialist at The Ohio State University Wexner Medical Center and Capricorn sun Rachel Stelzer joins the show to discuss all-things The Sea Goat in The Sign Series, a limited Astrocandy subseries that features each zodiac sign during its respective season.Make a to-do list and check it twice ‘cause it's Capricorn season! Capricorn (Dec. 21 - Jan. 20) is ruled by Saturn, the planet of discipline, responsibility and karma, so it's no wonder these earth signs work so hard– because they know hard work pays off (and pays the bills). You spent the Sagittarius season living life to the fullest, and now it's time to take life more seriously. Work to set new goals, create new habits and establish new routines in order to reap the rewards in the New Year. Learn from Rachel, a taskmaster Capricorn who planned her bachelorette, wedding shower, wedding and baby shower all in one year (that's A LOT of lists).In this episode, we discuss Capricorn's personality traits, strengths and weaknesses, likes and dislikes and how they show up in friendships and relationships. You'll also learn how you can tap into Capricorn energy to make the most of this goal-oriented season.Resources and references:Create your free Astrology birth chart HERESubscribe to Alice Bell's monthly astrological forecasts HEREIf you're looking for a space to connect in a spiritual community, you're cordially invited to The Astrocandy Social Club, a free, invite-only community group for people who love astrology, spirituality and mysticism. There's a multitude of categories and channels within the community to learn about and discuss with other ASC members, from astrology and manifestation to human design, tarot, holistic healing and more. Here, you can build community, share your wisdom, gain insights, create friendship and find yourself. Message @astrocandypodcast on Instagram to receive the exclusive link to join the community.About Astrocandy:Host Raven Brinson invites you on a mission of self-exploration and discovery through spiritual and mystical topics like astrology, holistic healing and wellness, manifestation, mindfulness and meditation, human design, chakra balancing and more.Connect with Astrocandy: Website: astrocandypodcast.comInstagram: HERE

On today's episode, meet Chyke Doubeni, MD, MPH. Dr. Doubeni is Chief Health Equity Officer at The Ohio State University Wexner Medical Center. Dr. Doubeni also serves as Associate Director for Diversity Equity and Inclusion in The Ohio State University Comprehensive Cancer Center. He is tasked with leading Ohio State's continued efforts to address the underlying drivers of disparities in health care that adversely impact marginalized groups and foster more equitable care and health outcomes. Dr. Doubeni is nationally recognized for his work in cancer prevention and public health. Dr. Doubeni received his Bachelor of Medicine, Bachelor of Surgery from the University of Lagos College of Medicine in Nigeria. After completing additional training in the United Kingdom, he completed a family medicine residency at Duke University and a preventive medicine residency at the University of Massachusetts, where he also earned a Master of Public Health degree.

This week we sit down with Sarah Hudson-DiSalle, PharmD, FACCC, and Jeffrey Pilz, PharmD, MPA, MS, BCPS, to discuss drug shortages.Sarah manages the Reimbursement Services and Medication Assistance Program for infusion services at the James Cancer Hospital and Wexner Medical Center at The Ohio State University. She oversees the reimbursement staff who obtain authorizations for infused medication and files medication denials at the James and Wexner Medical Center. She also oversees, coordinates, and advocates for the award-winning Medication Assistance Program for patients who cannot afford their infusion medications. Jeffrey Pilz, PharmD, MPA, MS, BCPS, currently serves as Assistant Director of Pharmacy for Medication Safety and Drug Policy at The Ohio State University Wexner Medical Center (OSUWMC) in Columbus, Ohio. In this role, he serves as co-chair for the OSUWMC Drug Shortages Committee and coordinates Department of Pharmacy initiatives around managing recent critical shortages.*This episode is brought to you by Cardinal Health. Cardinal Health™ Medically Integrated Dispensing Solutions helps your care team navigate industry complexities, optimize your processes and expand the amount of patients you serve. To connect with a Cardinal Health team member to learn more, go to cardinalhealth.com/dispensing.

In this episode, we are joined by Franklin Owusu, Administrator - Hospital Operations, The Ohio State University Wexner Medical Center, to discuss what his current role entails, challenges surrounding workforce shortages & financial pressures, his thoughts on tech & retail disruptors in healthcare, and more.Want to network with peers and hear more conversations like this? Apply to be one of our complimentary guest reviewers at our upcoming Annual Meeting April 3-6, 2023 here.

In this episode, we are joined by Dennis Delisle, ScD, FACHE, Executive Director at University Hospital & Ross Heart Hospital at The Ohio State University Wexner Medical Center, to discuss his background & current role, challenges surrounding workforce shortages, the growth of the academic medical center, and more.Want to network with peers and hear more conversations like this? Apply to be one of our complimentary guest reviewers at our upcoming Annual Meeting April 3-6, 2023 here.

In this episode, we are joined by Dennis Delisle, ScD, FACHE, Executive Director at University Hospital & Ross Heart Hospital at The Ohio State University Wexner Medical Center, to discuss his background & current role, challenges surrounding workforce shortages, the growth of the academic medical center, and more.Want to network with peers and hear more conversations like this? Apply to be one of our complimentary guest reviewers at our upcoming Annual Meeting April 3-6, 2023 here.

VIDEOS: The Cost of Denial Clip (17:33) Hang On, Bill Gates and Dr. Fauci just did WHAT? | Redacted with Clayton Morris (21:43) There is nothing constructive about the pot calling the kettle black. – Clare Daly  (1:17) Clinical trial for nicotinamide riboside: Vitamin safely boosts levels of important cell metabolite linked to multiple health benefits University of Iowa Health Care, October 10, 2022 In a clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage. Studies in mice have shown that boosting the levels of this cell metabolite — known as NAD+ — can produce multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. Levels of NAD+ diminish with age, and it has been suggested that loss of this metabolite may play a role in age-related health decline. These findings in animal studies have spurred people to take commercially available NR supplements designed to boost NAD+. However, these over-the-counter supplements have not undergone many clinical trials to see if they work in people. The new research, reported in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J. Carver Chair of Biochemistry at the University of Iowa Carver College of Medicine The human trial involved six men and six women, all healthy. Each participant received single oral doses of 100 mg, 300 mg, or 1,000 mg of NR in a different sequence with a seven-day gap between doses. After each dose, blood and urine samples were collected and analyzed to measure various NAD+ metabolites in a process called metabolomics. The trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses. “This trial shows that oral NR safely boosts human NAD+ metabolism,” Brenner says. “We are excited because everything we are learning from animal systems indicates that the effectiveness of NR depends on preserving and/or boosting NAD+ and related compounds in the face of metabolic stresses. Because the levels of supplementation in mice that produce beneficial effects are achievable in people, it appears than health benefits of NR will be translatable to humans safely.” Consumption of a bioactive compound from Neem plant could significantly suppress development of prostate cancer National University of Singapore, September 29, 2022 Oral administration of nimbolide, over 12 weeks shows reduction of prostate tumor size by up to 70 per cent and decrease in tumor metastasis by up to 50 per cent A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant or curry leaf common in throughout Indian cuisine, could reduce the size of prostate tumor by up to 70 per cent and suppress its spread or metastasis by half. In this research, we have demonstrated that nimbolide can inhibit tumor cell viability — a cellular process that directly affects the ability of a cell to proliferate, grow, divide, or repair damaged cell components — and induce programmed cell death in prostate cancer cells,” said Assoc Prof Sethi. The researchers observed that upon the 12 weeks of administering nimbolide, the size of prostate cancer tumor was reduced by as much as 70 per cent and its metastasis decreased by about 50 per cent, without exhibiting any significant adverse effects. “This is possible because a direct target of nimbolide in prostate cancer is glutathione reductase, an enzyme which is responsible for maintaining the antioxidant system that regulates the STAT3 gene in the body. The activation of the STAT3 gene has been reported to contribute to prostate tumor growth and metastasis,” explained Assoc Prof Sethi. “We have found that nimbolide can substantially inhibit STAT3 activation and thereby abrogating the growth and metastasis of prostate tumor,” he added. Mindfulness training provides a natural high, study finds University of Utah, October 20, 2022 New research from the University of Utah finds that a mindfulness meditation practice can produce a healthy altered state of consciousness in the treatment of individuals with addictive behaviors. Not unlike what one might experience under the influence of psychedelic drugs—achieving this altered state through mindful meditation has the potential lifesaving benefit of decreasing one's addictive behaviors by promoting healthy changes to the brain. The findings come from the largest neuroscience study to date on mindfulness as a treatment for addiction. The study, published in the journal Science Advances, provides new insight into the neurobiological mechanisms by which mindfulness treats addiction. Study findings provide a promising, safe and accessible treatment option for the more than 9 million Americans misusing opioids. Eric Garland is the lead author of the paper and is a distinguished professor and directs the University of Utah's Center on Mindfulness and Integrative Health Intervention Development. Garland's study builds on previous research measuring the positive effects of theta waves in the human brain. Researchers have found that individuals with low theta waves tend to experience a wandering mind, trouble concentrating or they ruminate on thoughts about themselves. Low theta waves result in a loss of self-control as the brain slips into its default mode of automatic habits. In contrast, when a person is focused, present and fully absorbed in a task, EEG scans will show increased frontal midline theta wave activity. “With high theta activity, your mind becomes very quiet, you focus less on yourself and become so deeply absorbed in what you are doing that the boundary between yourself and the thing you are focusing on starts to fade away. You lose yourself in what you are doing,” said Garland. Garland's new study showed it is in this mindful, theta wave state that people begin to experience feelings of self-transcendence and bliss, and the brain changes in ways that actually reduce one's addictive behaviors. Garland's research team recruited 165 adults with long-term opioid use for the study. Participants were randomly placed into either the control group that participated in supportive group psychotherapy or the experimental group taught to incorporate Mindfulness-Oriented Recovery Enhancement (MORE) into their daily lives. Participants showed more than twice as much frontal midline theta brain activity following treatment with MORE, whereas those in supportive therapy showed no increase in theta. Participants in MORE who showed the biggest increases in theta waves reported more intense experiences of self-transcendence during meditation, including the sense of one's ego fading away, a sense of oneness with the universe or feelings of blissful energy and love. MORE also led to significant decreases in opioid misuse through the nine-month follow-up. These reductions in opioid misuse were caused in part by the increases in frontal midline theta brain waves. Garland explained that by achieving “tastes of self-transcendence” through meditation, mindfulness therapy boosted theta waves in the frontal lobes of the brain to help participants gain self-control over their addictive behaviors. Free radicals blamed for toxic buildup in Alzheimer's brains Rutgers University, October 11, 2022. A study reported in Cell Death & Disease revealed a previously unknown mechanism that may contribute to traumatic brain injury and Alzheimer's disease. While a buildup of the protein amyloid-beta has been hypothesized to be the major driver of Alzheimer's disease, the study suggests that another protein, after undergoing oxidation by free radicals, could be a causative factor. “Indeed, scientists have known for a long time that during aging or in neurodegenerative disease cells produce free radicals,” explained lead researcher Federico Sesti, who is a professor of neuroscience and cell biology at Rutgers Robert Wood Johnson Medical School. “Free radicals are toxic molecules that can cause a reaction that results in lost electrons in important cellular components, including the channels.” Dr Sesti and colleagues determined that oxidation of a potassium channel known as KCNB1 results in a toxic buildup of this protein, leading to increased amyloid-beta production and damage to brain function. “The discovery of KCNB1's oxidation/build-up was found through observation of both mouse and human brains, which is significant as most scientific studies do not usually go beyond observing animals,” Dr Sesti reported. “Further, KCBB1 channels may not only contribute to Alzheimer's but also to other conditions of stress as it was found in a recent study that they are formed following brain trauma.” Study: Maternal, paternal exercise affects metabolic health in offspring Ohio State University, October 19, 2022 A mouse study by Kristin Stanford, with The Ohio State University College of Medicine at the Wexner Medical Center, provides new ways to determine how maternal and paternal exercise improve metabolic health of offspring. This study used mice to evaluate how their lifestyles—eating fatty foods vs. healthy and exercising vs. not—affected the metabolites of their offspring. Metabolites are substances made or used when the body breaks down food, drugs or chemicals, or its own fat or muscle tissue. This process, called metabolism, makes energy and the materials needed for growth, reproduction and maintaining health. Metabolites can serve as disease markers, particularly for type 2 diabetes and cardiovascular disease. “Tissue metabolites contribute to overall metabolism, including glucose or fatty acid metabolism, and thus systemic metabolism. We have previously shown that maternal and paternal exercise improve health of offspring. Tissue and serum metabolites play a fundamental role in the health of an organism, but how parental exercise affects offspring tissue and serum metabolites has not yet been investigated. This new data contributes to how maternal or paternal exercise could improve metabolism in offspring,” Stanford said. This study found that all forms of parental exercise improved whole-body glucose metabolism in offspring as adults, and metabolomics profiling of offspring serum, muscle, and liver reveal that parental exercise results in extensive effects across all classes of metabolites in all of these offspring tissues. Regular consumption of fried food before pregnancy increases risk of developing gestational diabetes Kennedy Shriver National Institute of Child Health and Human Development, October 10, 2022 New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that women who eat fried food regularly before conceiving are at increased risk of developing gestational diabetes during pregnancy. Gestational diabetes (GDM) is a complication that can arise during pregnancy, and is characterised by abnormally high blood glucose during the pregnancy (especially in the final 3 months). It can lead to increased birthweight of the child, as well jaundice and other complications. When left untreated, it can cause complications or stillbirth. Women who have GDM are more likely to later develop full blown type 2 diabetes. The authors included 21,079 singleton pregnancies from 15,027 women in the Nurses' Health Study II (NHS II) cohort. NHS II is an ongoing prospective cohort study of 116,671 female nurses in the USA aged 25-44 years at the start of study. For fried food consumption, participants were asked “how often do you eat fried food away from home (e.g. French fries, fried chicken, fried fish)?” and “how often do you eat food that is fried at home?” Both questions had four possible frequency responses: less than once per week, 1-3 times per week, 4-6 times per week, or daily. The researchers analysed fried food consumption at home and away from home separately, as well as total fried food consumption. In addition, they asked the participants what kind of frying fat/oils they usually used at home, with the possible responses as follows: real butter, margarine, vegetable oil, vegetable shortening, or lard. The association persisted after further adjustments were made for varying body-mass index (BMI). After this, the risk ratios of GDM among women who consumed total fried foods 1-3, 4-6, and 7 or more times per week, compared with those who consumed less than once per week, were 1.06, 1.14, and 1.88 respectively (thus an 88% increased risk for 7 or more times per week compared with less than once per week). The authors say: “The potential detrimental effects of fried food consumption on GDM risk may result from the modification of foods and frying medium and generation of harmful by-products during the frying process. Frying deteriorates oils through the processes of oxidation and hydrogenation, leading to an increase in the absorption of oil degradation products by the foods being fried, and also a loss of unsaturated fatty acids such as linoleic and linolenic acids and an increase in the corresponding trans fatty acids such as trans-linoleic acids and trans-linolenic acids.” They add: “Frying also results in significantly higher levels of dietary advanced glycation end products (AGEs), the derivatives of glucose-protein or glucose-lipid interactions. Recently, AGEs have been implicated in insulin resistance, pancreatic beta-cell damage, and diabetes, partly because they promote oxidative stress and inflammation. Moreover, intervention studies with a diet low in AGEs have shown significantly improved insulin sensitivity, reduced oxidant stress, and alleviated inflammation.” When analysed separately, the authors found that there was a statistically significant association of GDM with fried food consumption away from home, but not with fried food consumption at home. The authors say: “Deterioration of oils during frying is more profound when the oils are reused, a practice more common away from home than at home. This may partly explain why we observed a stronger association of GDM risk with fried foods consumed away from home than fried foods consumed at home.”

Phyllis Teater, CIO of The Ohio State Wexner Medical Center, joined the podcast to talk about how health system IT teams are changing and how digital health is evolving.

Dr. Anne Kloos received her physical therapy degree from the University of Wisconsin-Madison and her doctoral degree in biology/neuroscience from Cleveland State University. She is currently a Professor Clinical in the Physical Therapy Division at the Ohio State University (OSU) where she teaches adult neurorehabilitation and neuroscience courses. Her research is focused on balance and gait interventions in individuals with neurodegenerative diseases. She is a board-certified neurologic physical therapy specialist. Dr. Kloos has worked as a consultant physical therapist at the OSU Movement Disorders Clinic since 2005. She is the Co-Director of the Ohio State University Neurologic Physical Therapy Residency Program. Dr. Deb Kegelmeyer has over 30 year's clinical experience and is currently a Professor of Health and Rehabilitation Sciences at The Ohio State University. She has extensive clinical expertise having worked in acute care, out-patient therapy and spent 10 years as director of physical therapy at a skilled nursing facility. Currently she works as a consultant in the Huntington's Disease Center of Excellence at Wexner Medical Center, Ohio State University. She studies mobility and fall prevention in individuals with Huntington's Disease. Her publication titles include use of the Tinetti Mobility Test in Huntington's disease and use of Dance, Dance Revolution to improve balance in Huntington's disease. She is also a vice-chair of the European Huntington's Disease Network physiotherapy working group.

Dr. James Borchers is the President and CEO of the U.S. Council for Athletes' Health, as well as the Chief Medical Officer for the Big Ten Conference, physician and Director for the Division of Sports Medicine at the Wexner Medical Center, and a Professor of Clinical Family Medicine and Sports Medicine at the Ohio State University College of Medicine. He previously spent 18 years as a team physician for the Ohio State Athletics Department, including five as the head team physician and eight working with the football program. A former student-athlete, he played football at Ohio State while earning his undergraduate degree in Chemistry, before going on to earn his MD from Northeastern Ohio Universities College of Medicine and his Master of Public Health from Ohio State. He is board-certified in both family medicine and sports medicine and has been named one of the region's top doctors, as well as one of the Best Doctors in America.

Dr. James Borchers is the President and CEO of the U.S. Council for Athletes' Health, as well as the Chief Medical Officer for the Big Ten Conference, physician and Director for the Division of Sports Medicine at the Wexner Medical Center, and a Professor of Clinical Family Medicine and Sports Medicine at the Ohio State University College of Medicine. He previously spent 18 years as a team physician for the Ohio State Athletics Department, including five as the head team physician and eight working with the football program. A former student-athlete, he played football at Ohio State while earning his undergraduate degree in Chemistry, before going on to earn his MD from Northeastern Ohio Universities College of Medicine and his Master of Public Health from Ohio State. He is board-certified in both family medicine and sports medicine and has been named one of the region's top doctors, as well as one of the Best Doctors in America.

This episode features Jennifer Dauer, Chief Strategy and Transformation Officer at The Ohio State University Wexner Medical Center, and Jeff Copeland, Chief Business Development Officer at Bon Secours Mercy Health. Here, they discuss the Healthy State Alliance, a strategic initiative between The Ohio State University Wexner Medical Center and Bon Secours Mercy Health to transform Ohio's health as a whole with the current main focuses being COVID-19, the opioid epidemic, cancer care, health profession education, and more.

Phyllis Teater, CIO of The Ohio State Wexner Medical Center, joined the podcast to talk about how health system IT teams are changing and how digital health is evolving.

Please join author George Dangas and Associate Editor Brendan Everett as they discuss the article “Colchicine in Cardiovascular Disease.” Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-hosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center and Duke National University of Singapore. Dr. Greg Hundley: Welcome, everyone, to 2022. I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Carolyn, oh, we're starting off the year with a twist on the feature article. It's a review article on colchicine and cardiovascular disease. But before we get to that, how about we grab a cup of coffee and jump into some of the other articles in the issue? Dr. Carolyn Lam: Absolutely. The new year is starting off with a bonanza issue. This first topic is so important. We know that various non-invasive, intermittent rhythm monitoring strategies have been used to assess arrhythmia recurrences in atrial fibrillation ablation trials. But the question is, what is the frequency and duration of non-invasive rhythm monitoring that accurately detects arrhythmia recurrences and approximates the atrial fibrillation burden derived from continuous monitoring using the gold standard, implantable cardiac monitor? Now to answer this question, investigators Jason Andrade and colleagues from the Montreal Heart Institute, who looked at the rhythm history in 346 patients enrolled in the CIRCA-DOSE trial. They reconstructed the rhythm history using computer simulations and evaluated event-free survivals, sensitivity, negative predictive value, and AF burden in a range of non-invasive monitoring strategies including those used in contemporary AF ablation trials. Dr. Greg Hundley: Ah, very interesting, Carolyn. So what did they find? Dr. Carolyn Lam: Detection of arrhythmia recurrence following ablation was highly sensitive to the monitoring strategy employed between trial discrepancies and outcomes, in fact, may reflect these different monitoring protocols. Binary efficacy outcomes, such as time to AF recurrence, appeared to underestimate the true impact of catheter ablation on the burden of atrial arrhythmia. The most commonly performed intermittent rhythm monitoring techniques, like short duration 24- or 48-hour ambulatory Holter, they do miss a substantial proportion of arrhythmia recurrences and significantly overestimate the true AF burden in patients with recurrences. So based on measures of agreement, serial long-term, that is four seven-day or two 14-day intermittent monitors accumulating at least 28 days of annual monitoring provide estimates of AF burden that are comparable with the implantable cardiac monitor. However, implantable cardiac monitors outperform intermittent monitoring for arrhythmias and should be considered the gold standard for clinical trials. Dr. Greg Hundley: Very nice, Carolyn. It sounds like a lot of clarification on monitoring of AF burden. Well, my first paper comes to us from Dr. Prabhakara Nagareddy from The Ohio State University, The Wexner Medical Center. Carolyn, acute myocardial infarction results in an overzealous production and infiltration of neutrophils in the ischemic heart, and this is mediated in part by granulopoiesis induced by the S100A8/A9 NLRP3, IL-1 beta signaling axis in injury-exposed neutrophils. In this study, Carolyn, the investigators evaluated a hypothesis as to whether IL-1 beta is released locally within the bone marrow by inflammasome prime and reverse migrating neutrophils. Dr. Carolyn Lam: Ah, okay. So what did they find, Greg? Dr. Greg Hundley: Okay, Carolyn. In response to myocardial infarction, the NLRP3 inflammasome prime neutrophils upregulated CXCR4 and reverse migrated to the bone marrow, where they adhered to adhesion molecules like P-selectin on the bone marrow endothelial cells. Second, Carolyn, in the bone marrow, the inflammasome prime neutrophils released IL-1 beta through gasdermin-dependent conduit pores without undergoing the mandatory pyroptosis. Third, genetic and/or pharmacological strategies aimed at limiting reverse migration of inflammasome prime neutrophils to the bone marrow or release of IL-1 beta, both suppressed granulopoiesis and improved cardiac function in mouse models of myocardial infarction. So Carolyn, therefore, strategies aimed at targeting specific signaling pathways within the neutrophils or reducing retention of the inflammasome prime neutrophils in the bone marrow may provide novel avenues to regulate inflammation and improve cardiac outcomes. Dr. Carolyn Lam: Wow, neat, Greg. Thanks for explaining that so nicely. Well, the next paper deals with my favorite topic, heart failure with preserved ejection fraction of HFpEF, and this time looks at mechanisms of sinoatrial node dysfunction. The investigators, led by Dr. Cingolani from Smidt Heart Institute at Cedars-Sinai Medical Center, sought to investigate the role of the intrinsic pacemaker on chronotropic incompetence in HFpEF. They performed extensive sinoatrial node phenotyping, both at baseline and after stress in the well-characterized Dahl salt-sensitive rat model of HFpEF. These rats exhibited limited chronotropic response associated with intrinsic sinoatrial node dysfunction, including impaired beta-adrenergic responsiveness and an alternating leading pacemaker within the sinoatrial node. Prolonged sinoatrial node recovery time and reduced sinoatrial node sensitivity to isoproterenol were confirmed in the two hit mouse model. Adenosine challenge unmasked conduction blocks within the sinoatrial node, which were associated with structural remodeling. Finally, single-cell studies and transcriptomic profiling revealed HFpEF-related alterations in both the membrane clock or iron channels and the calcium clock of the spontaneous calcium release events. Dr. Greg Hundley: Wow, Carolyn, lot of really interesting data here. So what were the clinical implications? Dr. Carolyn Lam: Yeah, it's a really great study. Two models of HFpEF-consistent result in an important topic. Basically, here at the take-home messages. Provocative testing can be valuable to elicit functional abnormalities to facilitate HFpEF diagnosis and considering the exceptionally high clinical and epidemiologic convergence between AFib and HFpEF, sinoatrial node dysfunction may underlie the development of abnormal atrial rhythms in HFpEF. Dr. Greg Hundley: Very nice, Carolyn. More information on HFpEF, again, one of your favorite subjects. Next, we're going to turn to a paper from Dr. Jian Li from the Peking Union Medical College Hospital. Carolyn, doxycycline has previously been demonstrated in a retrospective study to be associated with greater survival in patients with light chain AL amyloidosis. Therefore, Carolyn, this group prospectively compared the efficacy of bortezomib, cyclophosphamide, dexamethasone, or cyclophosphamide B or D, and cyclophosphamide B or D combined with doxycycline for cardiac amyloidosis. Dr. Carolyn Lam: Cool. So what did they find, Greg? Dr. Greg Hundley: Carolyn, this was a multi-center, open-label, randomized controlled trial, and 140 patients underwent randomization. The primary outcome was two-year progression-free survival. Progression-free survival was defined as the time from randomization to death, hematologic progression or organ progression, and that's the heart, the kidney, or the liver. And so Carolyn, these investigators in this trial demonstrated that doxycycline combined with cyclophosphamide B or D failed to prolong progression-free survival or cardiac progression-free survival compared with cyclophosphamide B or D alone in patients with cardiac AL amyloidosis. So Carolyn, a negative study that's quite informative and a very nice editorial that accompanies this article pertaining to future directions for management of AL cardiac amyloid. Dr. Carolyn Lam: Indeed important. Thank you. And there are other important papers in today's issue. There's a Research Letter by Dr. Pfeffer on the impact of sacubitril/valsartan versus ramipril on total heart failure events in the PARADISE-MI trial. Dr. Greg Hundley: Great, Carolyn. In the nail bag, boy, I've got a big list today. First, Dr. Churchwell has an AHA update on the need for policy change to improve maternal cardiovascular health. Next, Dr. Piazza has a Perspective piece on expanding the role of coronary CT angiography in interventional cardiology. There's an ECG challenge from Dr. Yarmohammadi entitled “Dancing Bundles with Stable Sinus Rhythm.” And next, we have our own Darren McGuire who, in this issue for all of 2021, is really recognizing our outstanding reviewers. And we want to thank all the listeners and everyone that reviews for us in this journal. Such an important feature and aspect to the publication of the wonderful articles that we receive. And then finally, there are some highlights from the circulation family of journals. Well, Carolyn, how about we get on to that feature discussion and learn more about colchicine and its use in cardiovascular disease. Dr. Carolyn Lam: Let's go and a Happy New Year, again, everyone. Dr. Greg Hundley: Welcome listeners to this January 4th feature discussion. This week, we're deviating a little bit because we are going to have an author discuss one of our in-depth reviews. As you know, we select those occasionally where they're is a topic that's very relevant in cardiovascular medicine and an investigator or team of investigators or authors will put together a very nice review of a topic. This week, we're going to talk about colchicine, and we have with us Dr. George Dangas from the Icahn School of Medicine at Mount Sinai and our associate editor, Dr. Brendan Everett, who manages this paper and he is from Brigham and Women's Hospital. Welcome, gentlemen. George, we'll start with you. George, why colchicine? Can you tell us a little bit about mechanism of action? Tolerability? Why would we want to use this particular agent in patients with cardiovascular disease? Dr. George Dangas: Thank you very much for the opportunity to join this interesting podcast. Colchicine is indeed an interesting drug. It's been around for centuries, in all honesty. In general, I would say it's a mild anti-inflammatory and in general, it's rather well tolerated. We'll go into those perhaps a little bit later. The precise mechanism is actually interestingly not quite defined. It may have a few ways to act by blocking perhaps the chemotaxis of the leukocytes or the adhesion of the leukocytes or the ability to release their granules, et cetera, but there isn't a specific major one that is targeting. Perhaps, it's targeting more than one mechanism in a mild way, and I think that goes into each utility, as well as the absence of the major side effect that might limit it. Dr. Greg Hundley: Very nice. So you started to mention the word utility, so maybe let's go through some clinical indications, or clinical uses perhaps rather than indications, can you tell us a little bit about its use in individuals with pericarditis? Dr. George Dangas: I think this is where it started to enter the cardiovascular field because we all recognize that pericarditis is an inflammatory disease and inflammation of the pericardium of different reasons perhaps. And anti-inflammatory drug is rather fitted to treat an inflammatory disease and besides, it's not like we had any other drug, in all honesty. Clearly, recurrent pericarditis might be treated with steroids for example, but steroids is not something any cardiologist would jump as a first line and give high doses and all that. Colchicine made its way to pericarditis like acute or recurrent pericarditis, post-cardiac cardiology syndrome, restless syndrome or the specific post-cardiac surgery, major inflammation. And indeed has a daily dosage perhaps with some loading dose or double the daily dosage or something initially and then we give it for a prolonged period of time in order to suppress. I would say this is a reasonable choice rather than jumping to the steroid. And of course, you reserve the steroid for the, I would say, more severe or more recurrent cases. I think everybody understands this type of activity. There've been quite a few clinical studies in this aspect. Again, in the absence of a competitor, I think it's a winner in this area. Dr. Greg Hundley: Very nice. And then, how about atrial fibrillation? Are there uses of this colchicine in patients with atrial fibrillation? Dr. George Dangas: Well, again, it's very interesting that a lot of atrial fibrillation, it may be in some ways inflammatory in origin. And quite frankly, we had an interesting [inaudible 00:14:50] clinical trial in American Heart Association in 2021. I'd like to point out here, the study that postoperative atrial fibrillation was mitigated when, during cardiac surgery, there was a slicing of the posterior pericardial. This allowing the inflammation in some ways that's related there. To me, that was a very interesting observation, though I related to colchicine because it validates the fact that there is something inflammatory in pericardial that related with the postoperative atrial fibrillation. So along these lines, let's go back to colchicine, Afib, and postop Afib, and post-ablation I would say patients. Again, there are risks of some inflammation and that's where the theory of a mild, rather well-tolerated, anti-inflammatory might come in. And there's been few studies, not a large definitive study, but several studies that are the, I would say, component with interesting results with colchicine in these patients. Dr. Greg Hundley: Very good. Another area of cardiovascular disease that's emerging literally with some demonstrable results using colchicine is the realm of ischemic heart disease. Can you walk us through some of the utility myocardial infarction or maybe even post-percutaneous coronary artery intervention? Dr. George Dangas: Again, the hallmark in this type of diseases, cardiovascular disease or coronary heart disease, is the hallmark of role of inflammation in this disease. And we know very well from the studies of the C-reactive protein, importance is a marker of inflammation. Very, very important in the CAD as well as in even the treatment with the antibody canakinumab a little bit earlier in the CANTOS trial a few years earlier at the very high level inhibited inflammation had a benefit and colchicine comes in maybe a milder anti-inflammatory about this agent, but at the same time with significantly less cause and significantly better recognition among the clinicians and a lot less, I would say, tolerability problems or issues are less unknowns. And I think that's where it comes in. The difficulty has been that whenever you go to cardiovascular, the cardiovascular, I would say coronary artery disease specifically, ACS and all that, the level evidence required for the doctors to believe in a therapy is very different than the areas we discussed before where there's little bit of a pericardial disease, for example, not that many drugs, all of a sudden, coronary artery disease, the bar is so high, and that's where the difficulty has been. There've been several studies. They've been interesting results with some benefits, particularly due to the decrease in inflammation and the secondary prevention, one can say. That is really the hallmark of where it aims to benefit in the secondary prevention, but there hasn't been one massive study with clearly superb results. I would say adequately powered single study that is missing in some ways. But several studies have been, again, very, very encouraging, but we learned that there's no much point if loading a lot of doses of high doses of colchicine, and it's a little bit better, again, when you aim with a daily dose towards reduced recurrences, particularly if you started early after an acute event. Dr. Greg Hundley: Very nice. Well, listeners, we're going to now turn to our associate editor, Dr. Brendan Everett, from Brigham and Women's Hospital. Brendan, you have a lot of papers come across your desk. First and foremost, what attracted you to this particular article? Dr. Brendan Everett: Well, thanks, Greg. And kudos to George and his team for putting together a really nice paper. It's great to have this kind of paper come into my inbox. That's specifically because colchicine, I think, has exploded as a really important novel therapy even though the therapy itself is perhaps hundreds of years old, as you heard George say a moment ago, but its role in treating cardiovascular diseases has really begun to emerge rapidly. I think there's a tremendous amount of enthusiasm for other ways to treat our patients who have really a recalcitrant cardiovascular disease, whether that's pericarditis, atrial fibrillation or I think, importantly, ischemic heart disease, because that's such a common disease and something where we're always looking for new ways to help patients live longer with fewer recurrent events. And so this paper I thought did a really good job of capturing the existing evidence for these conditions and some others and giving us a sense of where the strengths of that evidence lay and where the weaknesses were. I thought particular strength was in the tables where the authors laid out each of the trials and the results of the trial, their endpoints, where the benefit was potentially. And also importantly, where risks were seen because I think that's one of the really important questions that remains open with respect to colchicine therapy when we begin to talk about using it in a vast population of people with stable ischemic heart disease or post-myocardial infarction ischemic heart disease. Dr. Greg Hundley: Brendan, tell us a little bit about those risks. Dr. Brendan Everett: I'd be happy to do that. I want to emphasize before I dive in that I think the benefits that George has laid out are important, and I don't want to overshadow what the major trials have seen. But I think the thing that it is at least a little bit of the fly in the ointment, if you will, for colchicine in ischemic heart disease is that a couple of the large trials have shown an increased risk of non cardiovascular mortality or bad non-cardiovascular outcomes. And that's of concern, I think, as we saw in the CANTOS trial, which was the monoclonal antibody trial for canakinumab that George mentioned earlier, there was an increase in infection-related mortality. And so whenever you use an anti-inflammatory drug, you're worried about whether or not you're blunting other compensatory mechanisms that the body has to protect against infection and other diseases. I think it's likely that these findings are the play of chance, but we don't know for sure. For example, in the COLCOT trial, which I think is probably the largest and most interesting trial, which was designed and run in Canada, there was a slightly higher level of pneumonia in patients who got active therapy as compared to placebo. And then, two of the trials that were published more recently including LoDoCo2, which was a trial of about 5,000 patients run in the Netherlands and Australia. There was actually a marginally increased risk of non-cardiovascular mortality. That didn't reach statistical significance, but it was awfully close, and I think it gave people some concern. And then, there was also the COPS trial. Again, all these are really outlined in wonderful detail in the manuscript where there was a slight increase of total death and non-cardiovascular death. These events are few, but they're in a direction in two trials, and so they make people a little bit worried. I think the other thing that I noticed was the high prevalence of myalgia as a side effect. I think, Greg, you're always interested in the clinical implications and yesterday I was in clinic and saw a young patient who had had pericarditis. He had been prescribed colchicine by his primary care physician, and he literally couldn't stand and walk up straight because of the amount of abdominal pain he had, which was unusual. To be honest, I've given colchicine to a hundred patients at least, and none of them have had that profound of a side effect, but it's at least worth considering that some patients will not tolerate the therapy because of adverse effects. Dr. Greg Hundley: Very good. Well, in just 30 seconds or so, for each of you, first George and then Brendan. George, balancing some of the efficacy and then some of the concerns, what do you see is the next studies to be performed really in this sphere of research? Dr. George Dangas: This is a great question. And indeed, the concerns one can say or the issues, I would say, regarding this drug, are indeed real because any drug that suppresses inflammation has this risk. There are two ways one can address those. One is with term administration. You don't prescribe it as an annuity forever, but you prescribe it in a three- to six-month or one-month or try to control the time. I think this is done in clinical practice, in all honesty. I don't think that people are prescribing colchicine for life. Same way when we prescribe statins, for example. On the other hand or from investigational point of view, I think the two sets of information we need and, in all honesty, when you investigate issues regarding mortality or these are rare events, there's only one. You need a very large trial or a very large register. A very large trial preferably and colchicine being an often genetic drug, funding sources are rather limited, but we have NIH chipping in with some funding periodically and that might really be needed. So I want to outline that in the last table of our very large, I would say large table of our manuscript but were very happily outlined many ongoing trials. There are, in atrial fibrillation, three coronary artery disease. One in PCI and two in stroke. Something we didn't touch up again. But again, there's the question of inflammation in stroke. I think there's a lot of work ongoing. Perhaps you can see some meta-analysis, again, in order to get a handle of those risks, but at a rather low rate. It's just a difficult thing to come around. Dr. Greg Hundley: Very good. Brendan, anything to add? Dr. Brendan Everett: I would just add I agree a hundred percent with George just said. I think the only missing piece there is heart failure, which I think is and many have shown that there's an inflammatory component to heart failure, whether it's heart failure with reduced ejection fraction or preserved ejection fraction. And the timing of when that intervention might be, whether it might be before the development of symptoms or because there's a lot of trials out there that have struggled with this question and have unfortunately failed to show any benefit, I would just encourage the listeners of the podcast to look at this paper because it's a really marvelous compilation of the evidence for what is a really hot topic in cardiovascular medicine, a really important topic for a lot of the reasons that George mentioned. It's just very well done and comprehensive. Again, kudos to the authors for making such a great effort at putting something together that has a lot of clinical relevance, I think, and also points the way forward for research as you ask, Greg. Dr. Greg Hundley: Very nice. Well, listeners, we want to thank Dr. George Dangas from Icahn School of Medicine in Mount Sinai and our own associate editor, Dr. Brendan Everett from Brigham and Women's Hospital for bringing us this data pertaining to colchicine benefits, as we know in acute and recurrent pericarditis, but also emerging indications related to post-procedural atrial fibrillation or coronary artery disease. And really, colchicine's targeting of cardiovascular inflammation is being helpful in those alleviating those processes. Well, on behalf of Carolyn and myself, we want to wish you a great week, and we will catch you next week on the run. Dr. Greg Hundley: This program, this copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

This episode features Robert Weber, Chief Pharmacy Officer at The Ohio State University Wexner Medical Center. Here he discusses his career journey, how his field has changed over the years, responsibilities in his role, and more.

This episode features Phyllis Teater, Chief Information Officer at the Ohio State University Wexner Medical Center. Here, she discusses what issues are currently most important to her, advice for young leaders, and more.

On this episode of Leadership Lessons in Health-System Pharmacy you will hear from Dan Like, Chief Administrative Officer, Ambulatory Services at the Ohio State University, as we discuss strategies for ambulatory care pharmacy leaders. Dan Like began at The Ohio State University Wexner Medical Center in 2000 in Quality and Operations Improvement, where he helped develop the Wexner Medical Center's first set of balanced scorecards that tracked overall performance across the academic medical center's key performance indicators spanning research, education and patient care. Dan was promoted to business manager of Information Technology and then to director of Strategic Planning and Business Development, where he helped lead the development of the medical center's first strategic planning process. This was a comprehensive process that went from identification and development of a new mission and vision statements, to overarching goals, to program development plans, and finally to performance measurements. In 2008, Dan was named executive director of Ambulatory Services to oversee the implementation of the ambulatory strategic plan and help form a new ambulatory services' business unit. Currently, Dan leads the operations and further growth and development of Ohio State's Ambulatory Services that has significantly grown to now include more than 2,000 employees, 250 clinics and outpatient services that generate more than two million outpatient visits per year. Dan received a bachelor's degree in Business from Miami University of Ohio, and a Master of Health Administration degree from The Ohio State University.

GoodAthleteProject.com For today's episode, Jim is joined by Dr. Robert Higgins, Director of the Department of Surgery at the Johns Hopkins University School of Medicine. Dr. Higgins is the leading authority in heart and lung transplantation, minimally invasive cardiac surgery, and mechanical circulatory support. His scientific interests include the mechanisms of cell injury in failing hearts, health economics and policy, racial disparities in post-transplant outcomes, access to care and improving outcomes among heart failure and cardiac surgery patients. Before his role at Johns Hopkins, Dr. Higgins served at The Ohio State University, where he was professor and chairman of the Department of Surgery, as well as surgeon-in-chief and director of the Comprehensive Transplant Center at Wexner Medical Center. Dr. Higgins obtained his bachelor's degree from Dartmouth College and went on to earn his medical degree from the Yale School of Medicine, followed by a master's degree in health services administration at Virginia Commonwealth University. He completed a residency in general surgery and served as chief resident at the University Hospitals of Pittsburgh. He was a Winchester Scholar and fellow in cardiothoracic surgery at the Yale School of Medicine. Dr. Higgins served as a senior registrar in transplantation at the renowned Papworth Hospital, the U.K.'s largest cardiothoracic surgical program and its main heart-lung transplant center. He also served as a Major in the United States Army Reserve Medical Corps. The Good Athlete Project on Instagram: @GoodAthleteProject and Twitter: @Coach4Kindness Visit us at our website: GoodAthleteProject.com

This episode features Dr. Harold Paz, Executive Vice President & Chancellor for Health Affairs and Chief Executive Officer Wexner Medical Center at The Ohio State University. Here, he discusses changes in healthcare delivery, thoughts on competition, and more.

This episode features Phyllis Teater, Chief Information Officer at the Ohio State University Wexner Medical Center. Here, she discusses what issues are currently most important to her, advice for young leaders, and more.

This episode features Dr. Harold Paz, Executive Vice President & Chancellor for Health Affairs and Chief Executive Officer at Wexner Medical Center at The Ohio State University. Here, he discusses changes in healthcare delivery, thoughts on competition, and more.

This episode features Dr. Harold Paz, Executive Vice President & Chancellor for Health Affairs and Chief Executive Officer Wexner Medical Center at The Ohio State University. Here, he discusses changes in healthcare delivery, thoughts on competition, and more.

Dr. Harold Paz, CEO of Wexner Medical Center at The Ohio State University, discusses Covid-19 variants, increasing vaccinations and the possibility of needing a booster. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Retail Reporter Matt Boyle explain how the position of the remote-work czar can be a shortcut to the C-suite. Bloomberg New Economy Editorial Director Andy Browne talks about the need for "Ping-Pong Diplomacy" between the U.S. and China. Bloomberg News Aerospace Reporter Julie Johnsson explains how Boeing is reeling from a brain drain on cutbacks and an Amazon talent grab. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Dr. Harold Paz, CEO of Wexner Medical Center at The Ohio State University, discusses Covid-19 variants, increasing vaccinations and the possibility of needing a booster. Bloomberg Businessweek Editor Joel Weber and Bloomberg News U.S. Retail Reporter Matt Boyle explain how the position of the remote-work czar can be a shortcut to the C-suite. Bloomberg New Economy Editorial Director Andy Browne talks about the need for "Ping-Pong Diplomacy" between the U.S. and China. Bloomberg News Aerospace Reporter Julie Johnsson explains how Boeing is reeling from a brain drain on cutbacks and an Amazon talent grab. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

This episode features Phyllis Teater, Chief Information Officer at The Ohio State University Wexner Medical Center. Here, she discusses the applications she’s most excited about, her career journey, and more.

How does a Music Education major end up becoming an internationally recognized leader in datacenter efficiency? In this #NomadFuturist podcast Kevin Kent takes us on an important environmental journey across the United States and around the world. Music and arts were a big part of Kent’s childhood and he studied music education in college. He soon realized he would face a life of limited financial prospects as a music teacher and so changed directions. He did a stint in banking where he became aware of data centers and found that he was fascinated by the mechanical and electrical aspects of the industry. He ultimately ended up at Ohio State supporting the data center for the Wexner Medical Center where he worked for nineteen years. Kent, an avid motorcyclist, saw first-hand the severe impacts of climate change as he traveled across the U.S. on vacations. He became increasingly concerned about the role of the data center as a contributor to the climate crisis. This concern led him to found Critical Facilities Efficiency Solutions (CFES), a global data center energy efficiency and sustainability consultancy service whose mission is to create data-driven, cost-effective, environmentally friendly and sustainable solutions. Phil, Nabeel and Kevin have a lively discussion about current data center trends. Kent talks about the challenges posed by an ever-increasing demand including issues of power usage inefficiencies. “We really have to start looking at where we are building our facilities, climate-wise, how close to the power generation source.”  He discusses the tremendous growth in the APAC region and highlights Africa as the next frontier, with the most projected growth over the next decade. Kent speaks about the impact of new technologies in achieving greater efficiencies and improved ROI, particularly machine learning which is seeing great results in the mechanical and electrical areas. Kent also discusses the power of predictive analytics for facilities staff: “You’re going to have insights into things that you’ve never had before!” Kent’s advice to young people who may be considering a career in critical infrastructure: “I think that the most important thing is to keep an open mind. Figure out what is important to you. Find people that you value and talk to them. Allow them to help you map out a plan.” Kevin Kent, Founder & CEO of Critical Facilities Efficiency Solutions, is recognized internationally as a leader in data center optimization, sustainability, and energy efficiency. He has an affiliation with several U.S. environmental foundations and is a Climate Reality Leader. Kent serves on the international Data Center Institute Board of Directors and is a global trainer for DCPro, providing critical training and certification for the data center industry. In 2020 he was recognized as a global Top 100 Tech Innovator and Influencer as well as the London Edge Conference Innovator of the Year. He is an international keynote speaker and has been featured in many tech magazines, blogs, webinars, and podcasts. Kent’s commitment to heal and protect our environment can be seen in many ways but none more visible than his donations to environmental foundations where thousands of trees have been planted as an incentive to data center owners who significantly reduce their data center carbon footprint. 

Dr. Harold Paz, CEO of Wexner Medical Center at The Ohio State University, explains how vaccinations can make it easier to fight Covid-19 variants. Bloomberg News Vancouver Bureau Chief Natalie Obiko Pearson explains why the anti-Asian hate crime capital of North America is Vancouver. Irina Novoselsky, CEO at CareerBuilder, discusses U.S. job growth significantly missing forecasts in April. Bloomberg News Technology Reporter Kurt Wagner talks about why Facebook isn’t going to apologize for creating Instagram youth. And we Drive to the Close with David Dietze, Senior Portfolio Strategist at Peapack Private Wealth Management. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.

Dr. Harold Paz, CEO of Wexner Medical Center at The Ohio State University, explains how vaccinations can make it easier to fight Covid-19 variants. Bloomberg News Vancouver Bureau Chief Natalie Obiko Pearson explains why the anti-Asian hate crime capital of North America is Vancouver. Irina Novoselsky, CEO at CareerBuilder, discusses U.S. job growth significantly missing forecasts in April. Bloomberg News Technology Reporter Kurt Wagner talks about why Facebook isn't going to apologize for creating Instagram youth. And we Drive to the Close with David Dietze, Senior Portfolio Strategist at Peapack Private Wealth Management. Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Dr. Harold Paz, CEO of Wexner Medical Center at The Ohio State University, provides a coronavirus and vaccine update. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Miami Bureau Chief Jonathan Levin talk about the story “As Wall Street Heads South, Florida Gets a Gold-Plated Makeover.” Bloomberg News Wall Street Reporter Sonali Basak breaks down bank earnings. And we Drive to the Close with Kara Murphy, CIO at Goldman Sachs Personal Financial Management. Hosts: Carol Massar and Tim Stenovec. Producer: Doni Holloway. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

On Episode 5 of Leadership Lessons in Health-System Pharmacy, you will hear from Hal Paz, MD, about a CEO's vision of pharmacy leadership success. Dr. Paz is the first to serve in the position of Executive Vice President and Chancellor for Health Affairs at The Ohio State University and Chief Executive Officer of the Ohio State Wexner Medical Center. In his current role, Dr. Paz leads all seven health science colleges and serves as CEO of the $4 billion Wexner Medical Center enterprise, which includes seven hospitals, a nationally ranked college of medicine, more than 20 research institutes, multiple ambulatory sites, an accountable care organization and a health plan. Dr. Paz has served on a number of corporate and scientific boards in the healthcare and biotechnology field. He has authored more than 100 publications, including peer-reviewed articles, chapters, commentaries and abstracts; he has also received numerous awards and an honorary degree. Relax and make yourself comfortable as you listen to our episode featuring Dr. Paz!

In this podcast, Phyllis Teater shares how she has worked with her team to manage through COVID. She also talks about the value of governance in creating buy-in for change; her passion for mentoring and servant leadership; and removing barriers in health IT.

Dr. Harold Paz, CEO of Wexner Medical Center at The Ohio State University, provides a coronavirus and vaccine update. Bloomberg Businessweek Editor Joel Weber and Businessweek Politics Editor Amanda Hurley discuss the story “The End of Steve Bannon—And Maybe Trump, Too.” We get Businessweek Economics with Danny Blanchflower, Professor of Economics at Dartmouth. And we Drive to the Close with Erika Klauer, Portfolio Manager at Jennison Associates. Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.  Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

When Dr. Hal Paz stepped into a newly created role at Ohio State University last June, he told Columbus Business First, “I want to be at the place that defines the next century of what healthcare looks like.” No one could have imagined this century. "What has happened in the past year is incredible, unbelievable, remarkable," Paz said, in the latest episode of Columbus Business First's Crisis Management podcast. "In part we got there because of this (coronavirus) pandemic, but a lot of it already was going through a process of change and, and the key ingredient in all this is innovation." For 13 months Paz has been the university's executive vice president and chancellor for health affairs, as well as CEO of its Wexner Medical Center. In that role, he has oversight of the $4 billion hospital system and faculty physician practice, plus the university health plan and all seven colleges in the health sciences – not just the medical school but nursing, pharmacy and other professions. The university's vision is to better integrate the training of those professionals, and the research by those disciplines, Paz said. "We have this new framework, this new vision for the future that I really am passionate about," he said. "This becomes the defining characteristic of what an academic health center is in the future. "How do you train a nurse and a doctor and a pharmacist and a public health worker and everyone involved in this process together at the same time – teaching them the same language, teaching them the same process of care from day one – as opposed to dropping them into a healthcare are setting and then retraining them or trying to understand why things are not lining up the way they should?" A physician and engineer, Paz came to Columbus after five years as chief medical officer for Aetna Inc. Before that he'd led a fellow Big Ten academic medical center and med school, Penn State. Our wide-ranging interview covers the response to the pandemic, the future of telemedicine, OSU's reinvigorated anti-racism agenda and much more.

Welcome to the only HerniaTalk LIVE session with interactive questions and answers to all of your hernia and hernia-related questions. Here, Dr. Jeffrey Janis, Board-certified plastic surgeon and abdominal wall reconstruction specialist at Wexner Medical Center at Ohio State University, joins us to answer your questions about hernia-related topics. We focused much of our talk on the role of the plastic surgeon in hernia repairs, the facility of tummy tucks and abdominoplasty to address diastasis recti and hernias, and the pros and cons of components separation surgery techniques. Each week we have more interesting discussions. Please LIKE and SHARE. If you are interested to learn more, go to www.HerniaTalk.com or visit my webpage www.beverlyhillsherniacenter.com.Follow Dr. Towfigh on the following platforms:Youtube | Facebook | Instagram | Twitter

Dr. Hal Paz- CEO of The Wexner Medical Center-Discusses Covid-19 and what the fine people at The Wexner Medical Center have been working on over the last year as Dr. Paz celebrates his 1 year anniversary!

Dr. Harold Paz, CEO of Wexner Medical Center at Ohio State University, discusses collaborating with community hospitals to fight COVID-19. Bloomberg Businessweek Editor Joel Weber and Bloomberg News Health Care Reporter Robert Langreth share their insight on Gilead's Remdesivir. We get Businessweek Economics with Dr. Ellen Hughes-Cromwick, Senior Resident Fellow at Third Way. She talks about the need for increased fiscal support from the U.S. government. And we Drive to the Close with Brad McMillan, CIO at Commonwealth Financial Network. Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.  Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

Dr. Joshua Joseph-Associate Professor of Medicine at OSU's Wexner Medical Center-Discusses what Diabetics can do to stay healthy during the pandemic.